Molecular modeling of drug delivery systems based on carbon nanostructures: structure, function, and potential applications for anticancer complexes of Pt(II)
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
The medication with Pt(II) drugs (cisplatin, carboplatin, and oxaliplatin) has been an effective
alternative for treating cancers due to their notable inhibition of cancer cells growth and the
prevention of metastasis. Nevertheless, the low selectivity of these metallodrugs for malignant
cells produces severe side effects, which limit this chemotherapy. In this context, carbon
nanohorns (CNHs) have been considered potential nanovectors for drugs, since they present
low toxicity, drug-loading capacity, biodegradation routes, and biocompatibility when
oxidized. However, there is still a lack of studies regarding the molecular behavior of these
nanocarriers on cell membranes. The present work aims to characterize the interactions between
inclusion complexes drug@CNH, which are formed by platinum drugs encapsulated in CNHs,
and plasma membranes by using molecular dynamics simulations. The results demonstrated
that the van der Waals contribution played a primary role (∼74%) for the complex stability,
which explain the confined dynamics of drugs inside the CNHs. The free energy profiles
revealed an endergonic character of the drug release processes from CNHs, in which the energy
barrier for oxaliplatin release (~24 kcal mol–1
) was ~30% larger than those for carboplatin and
cisplatin (~18 kcal mol-1
). The simulations also showed four stages of the interaction
mechanism CNH--membrane: approach, insertion, permeation, and internalization. Despite the
low structural disturbance of the membranes, the free energy barrier of ∼55 kcal mol-1 for the
CNHs translocation indicated that this transport is kinetically unfavorable by passive process.
The in silico experiments evidenced that the most likely mechanism of cisplatin delivery from
CNHs involve the approach and insertion stages, where the nanovector adheres on the surface
of cancer cells, as reported in in vitro studies. After this retention, the drug load may be slowly
released in the tumor site. Finally, simulations of the cellular uptake of Pt(II) drugs also pointed
out significant energy barriers (~30 kcal mol-1
) for this process, which reflects their low
permeability in membranes as discussed in experimental studies. In addition to reinforcing the
potential of CNH as nanovector of Pt(II) drugs, the results presented in this thesis may assist
and drive new experimental studies with CNHs, focusing on the development of less aggressive
formulations for cancer treatments.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

